10x Genomics Financial Statements
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics revenue and earnings
In fiscal 2025, 10x Genomics generated $642.8 million in revenue, up 5.2% from fiscal 2024. 10x Genomics reported a net loss of $43.5 million, compared with a loss of $182.6 million a year earlier. Gross margin was 69.1% (up from 67.9%) and operating margin -9.5%.
Diluted earnings per share came in at -$0.35. Over the last 5 fiscal years, TXG's revenue has grown at a 16.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 642.82M | 610.78M | 618.73M | 516.41M | 490.49M | 298.85M | 245.89M | 146.31M | 71.08M |
| Revenue growth (YoY) | +5.25% | -1.28% | +19.81% | +5.28% | +64.13% | +21.53% | +68.06% | +105.83% | — |
| Cost of Revenue | 198.94M | 196.30M | 209.41M | 120.39M | 74.09M | 58.47M | 61.03M | 28.66M | 10.56M |
| Gross Profit | 443.88M | 414.48M | 409.31M | 396.02M | 416.40M | 240.38M | 184.86M | 117.65M | 60.52M |
| Operating Expenses | 504.87M | 609.04M | 674.64M | 563.97M | 468.65M | 774.52M | 215.43M | 228.42M | 78.90M |
| Research & Development | 238.63M | 264.70M | 270.33M | 265.67M | 211.75M | 123.38M | 83.10M | 47.54M | 32.16M |
| Selling, General & Admin | 316.13M | 344.34M | 343.33M | 298.30M | 257.56M | 202.33M | 130.83M | 87.94M | 46.74M |
| Operating Income | -60.98M | -194.56M | -265.33M | -167.94M | -52.25M | -534.14M | -30.57M | -110.76M | -18.38M |
| Interest Expense | 0 | 4.00K | 33.00K | 476.00K | 866.00K | 1.68M | 3.08M | 2.41M | 811.00K |
| Other Income (Expense) | 21.08M | 16.86M | 16.57M | 5.97M | -1.46M | -334.00K | -460.00K | -1.63M | -366.00K |
| Pretax Income | -39.91M | -177.70M | -248.76M | -161.97M | -53.72M | -534.48M | -31.03M | -112.40M | -18.74M |
| Income Tax | 3.64M | 4.93M | 6.34M | 4.03M | 4.51M | 8.26M | 218.00K | 87.00K | 21.00K |
| Net Income | -43.54M | -182.63M | -255.10M | -166.00M | -58.22M | -542.73M | -31.25M | -112.48M | -18.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | -1.62 |
| EPS (Diluted) | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | -1.62 |
| Shares Outstanding (Basic) | 124.75M | 120.45M | 117.17M | 113.86M | 110.35M | 101.15M | 39.09M | 13.39M | 11.59M |
| Shares Outstanding (Diluted) | 124.75M | 120.45M | 117.17M | 113.86M | 110.35M | 101.15M | 39.09M | 13.39M | 11.59M |
| EBITDA | -24.79M | -158.68M | -229.82M | -142.58M | -31.14M | -520.13M | -23.51M | -106.86M | -14.07M |
| Gross Margin | 69.05% | 67.86% | 66.15% | 76.69% | 84.89% | 80.44% | 75.18% | 80.41% | 85.14% |
| Operating Margin | -9.49% | -31.85% | -42.88% | -32.52% | -10.65% | -178.74% | -12.43% | -75.70% | -25.85% |
| Net Margin | -6.77% | -29.90% | -41.23% | -32.15% | -11.87% | -181.61% | -12.71% | -76.88% | -26.39% |
This table shows 9 annual periods of 10x Genomics's income statement, from FY 2025 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TXG's reporting calendar. What is a income statement?